Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Revive Therapeutics Interview with CEO Mike Frank
https://thedalesreport.com/life-sciences/modernizing-old-medicine-to-treat-covid-19/
This board needs updating
SP is at .24 Canadian now
https://www.google.ca/search?safe=off&tbm=fin&sxsrf=ALeKk00sSzs6psMjO3YCWtqlW_bp8l-33w:1593974021441&q=CNSX:+RVV&stick=H4sIAAAAAAAAAONgecRowS3w8sc9YSn9SWtOXmPU5OIKzsgvd80rySypFJLmYoOyBKX4uXj10_UNDZPNCovyyvPMeBaxcjr7BUdYKQSFhQEANEbrhkkAAAA&sa=X&sqi=2&pjf=1&ved=2ahUKEwiu47z637bqAhUTHc0KHdR4DQEQlq4CegQIAxAf&biw=1920&bih=975&dpr=1#scso=_Cx0CX-25A9WGytMP4OyoiAo1:0
INVESTORS BEWARE: Case study of a CSE pump: RVV
Full report: https://twitter.com/cifccapital/status/1228736522343440384
Quoted below:
--------------------------------------------------------
Here's a live case study of a CSE pump: $RVV
A "cannabis life sciences company" (whatever that is) that is trading at a $4M market cap.
Suddenly announces a convert debt deal. 12% interest and convertible at .07c for the next 36months.
They offering is for all of 210K
--------------------------------------------------------
Then, they drop a PR that they have "entered in to an LOI w/ Red Holland to enter the psychedelic market"
Red Holland is a company that "plans to sell truffles"
As in, truffles. As in, nothing to do with psychedelics.
Here's a quote from the PR [...]
--------------------------------------------------------
So essentially $RVV has given 150K in stock @ .05c to Red Holland, who essentially says "we are trying to acquire a facility in Amsterdam and grow some truffles but right now all we have is absolutely nothing"
How is $RVV even allowed to put the word "psychedelics" in this PR?
--------------------------------------------------------
Then you dig deeper, the CEO of Red Holland is a guy who is juggling a radio show, being the IR person for $HALO.N and also the CEO of this company.
Okay well, no rules against that, so fair enough.
Then you look at who is leading the financing for Red Holland..
--------------------------------------------------------
First Republic Capital.
You may remember these guys from such deals as $HUGE $PUMP $GRAT and other deals that absolutely crushed any retail participants
Okay, well, everyone is allowed to take their chances and it is a free market so whatever.
Let's look at $RVV next PR..
--------------------------------------------------------
$RVV enters psychedelic market with LOI to acquire Psilocin Pharma Corp"
$2.75M price tag issued via 55M shares @.05c
Must be quite the enterprise here.
Except, Psilocin Pharma Corp appears to be nothing more than a website with a page called "Product Pipeline"
--------------------------------------------------------
In this product pipeline is "Hard shelled capsules" and "oral sprays" and "gel caps"
Nothing yet approved. Nothing yet operational. No IP or data which is unique or original.
So, where does the $2.75M price tag come from?
Good question for $RVV $RVV.C to answer
--------------------------------------------------------
So perhaps $RVV is acquiring a team? Maybe there's a lab with a bunch of scientists working day and night on disruptive plant medicines?
Well, looks like "Psilocin Pharma Corp" is actually just one person, who actually has a current full time job at a different cannabis company
--------------------------------------------------------
Point of all this being, PRs are easy to spin up, execution and building real value is hard.
Psychedelics is going to be the highest barrier to entry of any "start up" and everyone should call out these blatant pumps when they seem them. It's shameful.
And embarrassing.
--------------------------------------------------------
Printing up cheap paper and dishing it out like it's candy, all under the guise of "psychedelics" hoping to fool a few retail investors going "wow what a low market cap!" and ride the stock up a few multiples to sell in to unsuspecting investors.
Welcome to the CSE
--------------------------------------------------------
"Psilocin Pharma Corp" was registered 8 days ago.
https://nuans.com/auth/app/scr/corp/nuans/public/PreSearch.html?reportType=6&name=Psilocin+Pharma&src=%C2%A0%C2%A0%C2%A0Next%C2%A0%C2%A0%C2%A0
Credit: @_CrazedCanuck_
$2.75M for a business registered a week ago...
Got it.
Be better guys!
--------------------------------------------------------
Not sure needed day to cool RSI
Do you think we will close in the green today?
Beautiful!
Chugging along :)
Revive Therapeutics Appoints Blockchain Expert, Bernie Doyle, as Technical Advisor to Support Development of Medical Cannabis Patient-Focused Program Enabled by Blockchain and AI Technology
TORONTO, ONTARIO--(Marketwired - Nov. 21, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and pharmaceutical sectors, today announced that Mr. Bernie Doyle will join the Company as a Technical Advisor to support the development of the Company's proposed proprietary patient-focused program enabled by blockchain and artificial intelligence ("AI") dedicated to the medical cannabis sector.
"I am pleased that Bernie has joined Revive to assist with the development of our proposed patient-focused solution driven by blockchain and artificial intelligence, that will provide licensed producers of medical cannabis and healthcare professionals unique tools and authentic information to support their objective of giving the highest possible quality of care to patients," said Fabio Chianelli, President of Revive. "Bernie has significant experience and knowledge in the field of software and blockchain development and design. He will be instrumental in assisting Revive's initiatives in the development of a novel technology solutions to support our future medical cannabis products, healthcare professionals and licensed producers of medical cannabis."
"I am very excited to be a part of the Revive team as we work to develop a one-of-a-kind technology solution for the medical cannabis sector," said Bernie Doyle, Blockchain Technical Advisor for the Company. "I am pleased to utilize my expertise to pave the way for a proprietary blockchain technology solution that will ultimately drive the development and the use of novel, safe, consistent, and effective cannabinoid-based therapeutics."
The potential of a patient-focused program enabled by blockchain and AI technology for the medical cannabis sector is significant. Blockchain technology unlocks the potential to ensure the security of shared information, such as clinical data and user data throughout the product lifecycle, and allows for the potential of personalized care by enabling patients, healthcare professionals, researchers and licensed producers of medical cannabis to collaborate, to innovate and develop medical cannabis products in treating specific medical disorders, and to deploy individualized cannabis-based therapies based on authentic evidence of use of proprietary medical cannabis products, which is an important aspect of cannabis treatment due to the various cannabis strains and ratios that can be produced to provide optimal care to patients.
Bernie Doyle is a Certified Ethereum Blockchain Developer and owner of Refine Labs, a blockchain advisory, architecture and development company, and he is currently president of the Government Blockchain Association - Toronto chapter. With nearly 10 years of software development experience, Mr. Doyle has been also dedicated in delivering advanced educational presentations on ground-breaking software and cloud-based solutions, blockchain, distributed ledger technology and smart contracts for a number of sectors, including fintech and healthcare. Mr. Doyle is a thought leader in the field of blockchain and he is dedicated to being a leader in connecting and educating government, organizations, businesses and individuals about blockchain, and he is focused on developing novel uses of blockchain to a variety of sectors.
Nice buys coming in !!
Alright well, we will see what tomorrow has in store for rvv!
Damn right can’t wait
fiat currencies... that bitcoin money has to go somewhere
I buy silver also !!!
Yes I do agree. Off topic but, when I was younger I saved all my money a bought physical bars of silver still have it all ;)
Usually cannabis biotech make a jv with growers !! If we see that we could really run . Imho
Can you elaborate?
They just need to announce a grower for supply and this hit .75 easy just like TBPMF ...
I would like to know why it is going up too fast.
Very nice pipeline revive has, if they can execute. This stock will be over $1
I will have patience and hoping they will succeed.
What are you're thoughts of rvv? Ive been invested for awhile now. It's a long term play for me.
I am still here.
Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2017
TORONTO, ONTARIO--(Marketwired - Oct. 19, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs in the medical cannabis and cannabinoid pharmaceuticals sectors, today announced its results for the fiscal year ended June 30, 2017. The Audited Financial Statements and Management's Discussion and Analysis for the year ended June 30, 2017, may be viewed on SEDAR at www.sedar.com.
"I am pleased with how our focus on developing and commercializing novel cannabinoid-based therapies has evolved over this past year," said Craig Leon, Chief Executive Officer of Revive. "The value creating initiatives achieved for our medical cannabis and cannabinoid pharmaceuticals strategy such as the exclusive license and the research of cannabinoid-based therapies for liver diseases, the development of a unique delivery technology for cannabinoids, the relationships with scientific advisors, academia and industry, and the potential of future collaborations with companies seeking to develop and commercialize novel cannabinoid-based therapies effectively positions Revive in the medical cannabis and cannabinoid pharmaceuticals space for broad and large market opportunities."
Over the past year Revive has been focused on developing novel therapies that target the endocannabinoid system and building a robust cannabinoid-based product pipeline which includes early stage research and development programs with the advancement of cannabinoid-based therapies for liver diseases and potentially late stage commercial opportunities with the development of a unique cannabinoid delivery system for the medical cannabis market. Revive continues to dedicate its resources in identifying and researching novel cannabinoid-based therapies and in developing its cannabinoid delivery technology for both near-term commercial opportunities in the medical cannabis market and long-term opportunities in the cannabinoid pharmaceuticals market.
Operational Activities Achieved in 2017:
Engaged scientific advisors for cannabinoid-based therapies for liver diseases such as Dr. Scott Friedman, MD, Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, at the Icahn School of Medicine at Mount Sinai, Dr. Ram Subramanian, M.D, Associate Professor of Medicine and Surgery, and the Medical Director of Liver Transplantation at Emory Hospital and School of Medicine, Dr. Arun Sanyal, MD, Professor of Gastroenterology, Hepatology and Nutrition at the Virginia Commonwealth University (VCU) School of Medicine, and Dr. Pritesh Kumar, CEO PhytoSciences and an expert in cannabinoid pharmacology;
Entered into a research collaboration with Sanyal Biotechnology LLC for the development of cannabinoid-based therapies in the treatment of liver diseases such as autoimmune hepatitis (AIH), non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and fibrosis;
Entered into an exclusive license agreement with South Carolina Research Foundation for the development and commercialization of cannabidiol in the treatment of autoimmune disease, a rare liver disease;
Entered into an option to license agreement with Wisconsin Alumni Research Foundation for its Chitosan-Tannin delivery technology for the potential development and commercialization of a novel cannabinoid delivery technology; and
Entered into a sponsored research agreement with the University of Wisconsin-Madison to evaluate the Chitosan-Tannin delivery technology with a focus on cannabinoids for the potential to treat various diseases such as pain and skin disorders for the medical cannabis and cannabinoid pharmaceuticals markets.
Additional Operational Highlights
Revive announced the US FDA acceptance of its Investigational New Drug (IND) application and the initiation of the Phase 2 Study of REV-004 (Bucillamine) for the treatment of Cystinuria, and named Dr. David S. Goldfarb, MD, as Principal Investigator;
Revive announced the engagement of NYU School of Medicine and Massachusetts General Hospital for the Cystinuria Phase 2 Study;
Revive announced positive preclinical study results from its Rett Syndrome program; and
Revive Transferred the rights to the Rett Syndrome program to a third-party for an undisclosed one-time amount.
Financial Highlights
Cash and cash equivalents for the fiscal year ended June 30, 2017 totaled $1,768,676, compared to $1,333,239, for the year ended June 30, 2016;
Net loss for the fiscal year ended June 30, 2017 was $1,615,900, compared to a net loss of $2,737,932, for the year ended June 30, 2016. The decrease consisted primarily of research costs and professional fees; and
The Company's Research costs for the fiscal year ended June 30, 2017 were $408,216, compared to $1,568,288, for the year ended June 30, 2016.
About Revive Therapeutics Ltd.
Revive is focused on the research, development and commercialization of novel treatments for serious and unmet medical needs in the medical cannabis and cannabinoid pharmaceuticals markets by identifying and investigating potential therapies targeting the endocannabinoid system, such as cannabinoids, that may be repurposed for new indications, be delivered in a different way, combined with existing drugs, or be developed as new chemical entities. Additional information on Revive is available at www.ReviveThera.com.
Revive Therapeutics Announces Positive Results of its Novel Cannabinoid Delivery Technology
- Today announced positive initial results from its research project with the University of Wisconsin-Madison for the development of a novel cannabinoid delivery technology.
Revive Therapeutics Enters into Research Collaboration with Sanyal Biotechnology for Liver Diseases. Focused on advancing cannabinoids for the potential treatment of liver diseases.
Revive Therapeutics Applies to FDA for Orphan Drug Designation for Treatment of Autoimmune Hepatitis - Click here for more information
Revive Therapeutics and South Carolina Research Foundation Enter into Exclusive License Agreement for Cannabinoids-Based Therapeutics in the Treatment of Liver Diseases: Corporate Presentation
I got in at .20 and was out .26 - might get in if it starts to really move..
With the volume I thought we would be at .30 But .35 by end of next week would be fine by me .
Love the support for this company. Wouldn't dip below .22 over the last months and then steady support yesterday after a big spike. We should be around .35 by next week.
Would love to see plus .30 today for a bit of momentum into the weekend.
Ya some stocks no one wants to talk about on ihub for some reason. Stockhouse has lot of people talking about each stock but the garbage on there makes it intolerable... What possible news do we have coming up for RVV? I'm feeling good about holding this stock, lots of promise in the pipeline.
Very quiet board...and waiting for a further comment about the Inmed agreement.
News should be coming sometime this week. On Feb 22nd, Revive and InMed will endeavor to enter into a definitive agreement within 30 days of the execution of the term sheet. Pursuant to the signing of a definitive agreement, InMed will grant Revive the exclusive worldwide rights to develop and commercialize the target cannabinoid(s)
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
78
|
Created
|
02/19/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |